Lexeo Therapeutics to Present LX2006 Data at Parkinson's Congress

Lexeo Therapeutics will present oral data on its LX2006 treatment at the International Congress of Parkinson's Disease and Movement Disorders. The presentation will highlight previously reported data showing early stabilization or improvement in mFARS scores for LX2006-treated participants compared to a control cohort, and will include new mFARS subscore analyses.